Toll

Goodness Growth Holdings Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, April 1, 2024
Interest, International, Goodness, Tenant, Sale, Treasury, Toll, Event, Biomass, Property management

MINNEAPOLIS, April 01, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today reported financial results for its fourth quarter and full year ended December 31, 2023. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.

Key Points: 
  • 2"A Flower" refers to produced biomass that meet the Company's highest internal standards for flower quality, size, and appearance.
  • As of December 31, 2023, total current assets were $148.9 million, including cash on hand of $16.0 million.
  • As of December 31, 2023, the Company had a total of 232,799,343 shares outstanding on the treasury method basis.
  • ET (3:30 p.m. CT) to discuss its financial results for its fourth quarter and full year ended December 31, 2023.

Knowles to Release First Quarter 2024 Financial Results on May 1, 2024

Retrieved on: 
Monday, April 8, 2024
Automotive Manufacturing, Consumer Electronics, Aerospace, Technology, Manufacturing, Semiconductor, Telecommunications, Packaging, Engineering, Mobile, Wireless, Hardware, ID, MEMS, Corporation, Radio, Toll, Communications satellite

Knowles Corporation (NYSE: KN), a leading global supplier of high performance components and solutions, including ceramic capacitors and radio frequency (“RF”) filters, advanced medtech microphones and balanced armature speakers and MEMS microphones for the consumer electronic market, today announced the date for the release of its first quarter 2024 financial results.

Key Points: 
  • Knowles Corporation (NYSE: KN), a leading global supplier of high performance components and solutions, including ceramic capacitors and radio frequency (“RF”) filters, advanced medtech microphones and balanced armature speakers and MEMS microphones for the consumer electronic market, today announced the date for the release of its first quarter 2024 financial results.
  • Knowles will issue its first quarter 2024 financial results on May 1, 2024, immediately after market close followed by a conference call at 3:30 p.m. Central time (4:30 p.m. Eastern time) to discuss the results and company outlook.
  • The conference ID is 3966457 followed by # key.
  • A webcast replay will also be accessible via the Knowles website at http://investor.knowles.com for a limited time.

Goodness Growth Holdings Reschedules Fourth Quarter and Full Year 2023 Results Call to April 1, 2024

Retrieved on: 
Monday, March 25, 2024
Event, International, Interest, Toll

MINNEAPOLIS, March 25, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that, due to scheduling conflicts, it has rescheduled its fourth quarter and full year results conference call for the year ended December 31, 2023 to Monday, April 1, 2024 after the market closes.

Key Points: 
  • MINNEAPOLIS, March 25, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that, due to scheduling conflicts, it has rescheduled its fourth quarter and full year results conference call for the year ended December 31, 2023 to Monday, April 1, 2024 after the market closes.
  • Goodness Growth management will host a conference call with the investment community that day, Monday, April 1, 2024 at 4:30 p.m.
  • ET (3:30 p.m. CT) to discuss its results.
  • Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

Goodness Growth Holdings to Release Fourth Quarter and Full Year 2023 Results on March 28, 2024

Retrieved on: 
Thursday, March 14, 2024
Event, International, Interest, Toll

MINNEAPOLIS, March 14, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that it will release its financial results for its fourth quarter and full year ended December 31, 2023 on Thursday, March 28, 2024 after the market closes.

Key Points: 
  • MINNEAPOLIS, March 14, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that it will release its financial results for its fourth quarter and full year ended December 31, 2023 on Thursday, March 28, 2024 after the market closes.
  • Goodness Growth management will host a conference call with the investment community that same day, Thursday, March 28, 2024 at 4:30 p.m.
  • ET (3:30 p.m. CT) to discuss its results.
  • Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Retrieved on: 
Tuesday, March 26, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Microangiopathic hemolytic anemia, Incidence, Headache, Patient, Thrombotic thrombocytopenic purpura, Constipation, Mortality, Head, TTP, Nausea, Toll, Heart, Safety, Itch, Thrombocytopenia, Hypertension, Pharmaceutical industry

Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.

Key Points: 
  • Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
  • cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.2 It is associated with acute events and debilitating chronic symptoms or thrombotic thrombocytopenic purpura (TTP) manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, headache and abdominal pain.2,3,4 When left untreated, acute TTP events have a mortality rate of >90%.2,4
    “The approval of ADZYNMA is an important milestone for people living with cTTP in Japan, who had limited treatment options and now have the first treatment option specifically approved to treat this ultra-rare condition,” said Yasushi Kajii, Head, R&D Japan Region at Takeda.
  • “Developing innovative treatments that make a difference in the lives of patients is at the heart of what we do.
  • In Period 3, the incidence of TEAEs was 2.8% (1/36) in this drug group: nausea and headache (1 subject each).6
    This approval does not result in any changes to Takeda’s consolidated forecast for the fiscal year ending March 31, 2024 (FY2023).

NOTICE OF FIRST QUARTER RESULTS CONFERENCE CALL

Retrieved on: 
Wednesday, April 3, 2024
Webcast, The Company, TSX, WFG, Eastern Time Zone, McLaren, Toll

VANCOUVER, BC, April 3, 2024 /PRNewswire/ -.West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") (TSX and NYSE: WFG) will hold an analysts' conference call to discuss first quarter 2024 financial and operating results on Wednesday, April 24, 2024 at 7:00 a.m. Pacific Time/10:00 a.m. Eastern Time.

Key Points: 
  • VANCOUVER, BC, April 3, 2024 /PRNewswire/ -.West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") (TSX and NYSE: WFG) will hold an analysts' conference call to discuss first quarter 2024 financial and operating results on Wednesday, April 24, 2024 at 7:00 a.m. Pacific Time/10:00 a.m. Eastern Time.
  • To participate in the call, please dial:  1-888-390-0605 (Toll-free North America) or (416) 764-8609 (Toll number) or connect on the webcast.
  • Please let the operator know you wish to participate in the West Fraser conference call chaired by Mr. Sean McLaren, President and Chief Executive Officer.
  • West Fraser's first quarter 2024 financial and operating results will be released on Tuesday, April 23, 2024.

SOHU.COM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 UNAUDITED FINANCIAL RESULTS

Retrieved on: 
Monday, March 4, 2024
Online, ADS, Total, Changyou, PIN, APA, IPS, Investment, Share repurchase, Instability, Table, Annual report, MAU, Advertising, Income tax, GAAP, Bankruptcy, TLBB, TCJA, Toll, Bank statement, Video game

Thanks to these efforts, our bottom-line performance hit the high end of our guidance for the fourth quarter of 2023.

Key Points: 
  • Thanks to these efforts, our bottom-line performance hit the high end of our guidance for the fourth quarter of 2023.
  • GAAP operating loss was US$25 million, compared with an operating loss of US$6 million in the fourth quarter of 2022 and an operating loss of US$21 million in the third quarter of 2023.
  • Non-GAAP operating loss was US$26 million, compared with an operating loss of US$5 million in the fourth quarter of 2022 and an operating loss of US$20 million in the third quarter of 2023.
  • GAAP income tax expense was US$14 million, compared with income tax expense of US$7 million in the fourth quarter of 2022 and income tax expense of US$15 million in the third quarter of 2023.

Todd Friedland, John Stephens Named to 2024 Southern California Super Lawyers List

Retrieved on: 
Tuesday, February 13, 2024
Toll, Lawyer, Fraud, AV, Thomson Reuters, Transport, Research, Martindale-Hubbell, Property management

COSTA MESA, Calif., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Southern California-based Stephens Friedland | FBFK Law Firm today announced that shareholder/attorneys Todd Friedland and John Stephens have been selected to the distinguished 2024 Edition of the Southern California Super Lawyers list. This is Friedland's 13th consecutive year and Stephens's 8th consecutive year on the list.

Key Points: 
  • COSTA MESA, Calif., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Southern California-based Stephens Friedland | FBFK Law Firm today announced that shareholder/attorneys Todd Friedland and John Stephens have been selected to the distinguished 2024 Edition of the Southern California Super Lawyers list.
  • Super Lawyers is a ranking of outstanding lawyers who have attained a high degree of peer recognition and professional achievement.
  • Of those nominated, only five percent of the attorneys in Southern California are selected for inclusion.
  • Friedland was also named to the Super Lawyers' 2024 Top 50: Orange County and Business Litigation Lawyers list.

CURO to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 7, 2024

Retrieved on: 
Monday, January 22, 2024
Banking, Professional Services, Finance, Toll, Conference, Webcast, Cryptocurrency

CURO Group Holdings Corp. (NYSE: CURO) (“CURO”), an omni-channel consumer finance company serving consumers in the U.S. and Canada, announced today that its fourth quarter and full year 2023 financial results will be released before market open on Wednesday, February 7, 2024.

Key Points: 
  • CURO Group Holdings Corp. (NYSE: CURO) (“CURO”), an omni-channel consumer finance company serving consumers in the U.S. and Canada, announced today that its fourth quarter and full year 2023 financial results will be released before market open on Wednesday, February 7, 2024.
  • CURO will host a conference call to discuss its results at 8:00 a.m. Eastern Time on Wednesday, February 7.
  • The live webcast of the call can be accessed at the CURO Investors website at http://ir.curo.com/ , along with CURO’s earnings press release, and presentation slides.
  • An archived version of the webcast will be available on the CURO Investors website for 90 days.

Knowles to Release Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024

Retrieved on: 
Thursday, January 18, 2024
Mobile, Wireless, Hardware, Consumer Electronics, General Automotive, Technology, Automotive, Semiconductor, Packaging, Engineering, Automotive Manufacturing, Aerospace, Telecommunications, Manufacturing, Toll, Radio, Corporation, ID

Knowles Corporation (NYSE: KN), a leading global supplier of high performance components and solutions, including ceramic capacitors and radio frequency (“RF”) filters, advanced medtech microphones and balanced armature speakers and audio solutions, today announced the date for the release of its fourth quarter and full year 2023 financial results.

Key Points: 
  • Knowles Corporation (NYSE: KN), a leading global supplier of high performance components and solutions, including ceramic capacitors and radio frequency (“RF”) filters, advanced medtech microphones and balanced armature speakers and audio solutions, today announced the date for the release of its fourth quarter and full year 2023 financial results.
  • Knowles will issue its fourth quarter and full year 2023 financial results on February 7, 2024, immediately after market close followed by a conference call at 3:30 p.m. Central time (4:30 p.m. Eastern time) to discuss the results and company outlook.
  • The conference ID is 3966457 followed by # key.
  • A webcast replay will also be accessible via the Knowles website at http://investor.knowles.com for a limited time.